Tirzepatide
Dual GIP and GLP-1 Receptor Agonist
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Available as FDA-approved Mounjaro® for Type 2 diabetes and Zepbound® for weight management and obstructive sleep apnea. It provides superior weight loss and glycemic control compared to single-pathway medications through its unique dual mechanism of action.
Comprehensive Dosing Guide
Administration Guidelines
Proper administration technique is crucial for medication effectiveness and safety. Follow these guidelines for optimal results.
Injection Sites:
- Abdomen (belly area, avoiding 2 inches around navel)
- Thigh (front and outer areas)
- Upper arm (back/outer area)
Rotation Schedule:
- Rotate injection sites weekly
- Use different areas within the same site
- Avoid areas with scars, moles, or irritation
Timing:
- Administer on the same day each week
- Can be taken with or without food
- Choose a convenient day and stick to it
Medical Disclaimer
Tirzepatide is FDA-approved as Mounjaro® for Type 2 diabetes and Zepbound® for chronic weight management. This information is for educational purposes and should not replace consultation with healthcare providers. Individual results may vary. Prescribing information and medical supervision are required for all therapeutic uses.